세계의 폐렴구균 백신 시장 - 예측(2025-2030년)

The global pneumococcal vaccine market is forecasted to rise at a 6.23% CAGR, reaching USD 13.607 billion by 2030 from USD 10.058 billion in 2025.

Pneumococcal vaccines are designed to prevent disease caused by the bacterium Streptococcus pneumoniae. While pneumococcal diseases are common in young children, adults and the elderly demonstrate a higher susceptibility to severe contamination and mortality. Immunization is widely recognized as a critical public health measure to prevent the spread of such diseases, thereby driving consistent demand for pneumonia vaccines. The market's expansion is supported by several key factors, including the implementation of regular vaccination programs under national policies, rising public awareness against pneumonia, and strategic directives launched by international bodies like the World Health Organization (WHO) and UNICEF, often backed by increasing government support.

Primary Market Growth Drivers

A significant driver for the global pneumococcal vaccine market is the substantial incidence of childhood pneumonia. Among all infectious diseases affecting children, pneumonia is a leading cause of mortality globally. The high number of fatalities, particularly among children under the age of five, creates an urgent public health imperative to combat child mortality rates. This alarming situation is expanding the demand for effective prophylactic measures, thereby stimulating market growth for pneumococcal vaccines. The incidence rates are notably higher in certain regions, such as South Asia and West and Central Africa, which further underscores the need for widespread vaccination efforts.

Concurrently, growing disease awareness campaigns and supportive government policies are providing new growth prospects. Pneumococcal vaccines are primarily administered to children to protect them from illness, prompting international organizations to collaborate with national governments to reduce infection rates, especially among vulnerable populations. The implementation of nationwide vaccine programs, such as the expansion of pneumococcal conjugate vaccine (PCV) under universal immunization initiatives, aims to spread awareness and boost children's immune systems. These plans and policies invigorate the vaccine market by facilitating the introduction of novel products and the expansion of existing portfolios. Furthermore, aid from international organizations to underdeveloped countries with high pneumonia prevalence rates is contributing to an upward market trajectory by increasing vaccine accessibility.

Market Segment Analysis

The global pneumococcal vaccine market is segmented by type into conjugate vaccines and polysaccharide vaccines. The conjugate vaccine segment is anticipated to demonstrate remarkable growth. This segment's expansion is fueled by the vaccine's efficacy in providing immunity against serious diseases such as pneumonia and meningitis, which predominantly affect infants and older adults. Ongoing research and development efforts to enhance these vaccines continue to provide a major boost to the segment's growth, with new approvals expanding their protective coverage against a broader range of pneumococcal serotypes.

Geographically, the market is analyzed across North America, South America, Europe, the Middle East and Africa, and the Asia Pacific. North America is estimated to constitute a remarkable market share. This dominance is fueled by concerted efforts to reduce the spread of pneumonia among children and adults, leading regulatory authorities to grant approvals for new and advanced vaccines. The presence of major biotech and pharmaceutical manufacturers actively engaged in vaccine development further solidifies the region's market position. The ongoing development of pneumococcal vaccines, coupled with the persistent prevalence of the disease, continues to drive overall market growth in North America.

Market Restraints

A primary restraint on the global pneumococcal vaccine market is the high cost associated with vaccine production. The process of developing a vaccine is not only expensive but also involves a long duration, requiring passage through various phases of rigorous testing and monitoring to ensure safety and efficacy. This time-consuming and capital-intensive nature presents a significant challenge to market growth. However, this hurdle is partially mitigated by government subsidies for vaccine production and funds released by international organizations, which help to support the development and distribution pipeline.

Key Market Developments

The market is characterized by continuous activity from key players, focusing on the development and commercialization of advanced vaccine candidates. Recent strategic developments include positive regulatory opinions for new vaccines that offer broader protection against invasive diseases across various age groups, from infants to adults. Furthermore, companies are entering into commercial manufacturing agreements to bolster the production and commercialization of their pneumococcal conjugate vaccine candidates. Such collaborations leverage established manufacturing infrastructure and expertise to ensure scalable supply and meet global demand, reflecting a dynamic and forward-looking industry landscape.

Key Benefits of this Report:

• Insightful Analysis: Gain detailed market insights covering major as well as emerging geographical regions, focusing on customer segments, government policies and socio-economic factors, consumer preferences, industry verticals, and other sub-segments.
• Competitive Landscape: Understand the strategic maneuvers employed by key players globally to understand possible market penetration with the correct strategy.
• Market Drivers & Future Trends: Explore the dynamic factors and pivotal market trends and how they will shape future market developments.
• Actionable Recommendations: Utilize the insights to exercise strategic decisions to uncover new business streams and revenues in a dynamic environment.
• Caters to a Wide Audience: Beneficial and cost-effective for startups, research institutions, consultants, SMEs, and large enterprises.

What do businesses use our reports for?

Industry and Market Insights, Opportunity Assessment, Product Demand Forecasting, Market Entry Strategy, Geographical Expansion, Capital Investment Decisions, Regulatory Framework & Implications, New Product Development, Competitive Intelligence

Report Coverage:

• Historical data from 2022 to 2024 & forecast data from 2025 to 2030
• Growth Opportunities, Challenges, Supply Chain Outlook, Regulatory Framework, and Trend Analysis
• Competitive Positioning, Strategies, and Market Share Analysis
• Revenue Growth and Forecast Assessment of segments and regions including countries
• Company Profiling (Strategies, Products, Financial Information, and Key Developments among others.

The Global Pneumococcal Vaccine market is segmented and analyzed as follows:

• PNEUMOCOCCAL VACCINES MARKET BY TYPE
• Conjugate Vaccines
• Polysaccharide Vaccines
• PNEUMOCOCCAL VACCINES MARKET BY APPLICATION
• Routine Vaccination
• Vaccination For Disease/Infection
• PNEUMOCOCCAL VACCINES MARKET BY GEOGRAPHY
• North America
• USA
• Canada
• Mexico
• South America
• Brazil
• Argentina
• Others
• Europe
• Germany
• France
• United Kingdom
• Spain
• Others
• Middle East and Africa
• Saudi Arabia
• UAE
• Others
• Asia Pacific
• China
• India
• Japan
• South Korea
• Indonesia
• Thailand
• Others

TABLE OF CONTENTS

1. EXECUTIVE SUMMARY

2. MARKET SNAPSHOT

• 2.1. Market Overview
• 2.2. Market Definition
• 2.3. Scope of the Study

2.4. Market Segmentation

3. BUSINESS LANDSCAPE

• 3.1. Market Drivers
• 3.2. Market Restraints
• 3.3. Market Opportunities
• 3.4. Porter's Five Forces Analysis
• 3.5. Industry Value Chain Analysis
• 3.6. Policies and Regulations
• 3.7. Strategic Recommendations

4. TECHNOLOGICAL OUTLOOK

5. PNEUMOCOCCAL VACCINES MARKET BY TYPE

• 5.1. Introduction
• 5.2. Conjugate Vaccines
• 5.3. Polysaccharide Vaccines

6. PNEUMOCOCCAL VACCINES MARKET BY APPLICATION

• 6.1. Introduction
• 6.2. Routine Vaccination
• 6.3. Vaccination For Disease/Infection

7. PNEUMOCOCCAL VACCINES MARKET BY GEOGRAPHY

• 7.1. Introduction
• 7.2. North America
  • 7.2.1. USA
  • 7.2.2. Canada
  • 7.2.3. Mexico
• 7.3. South America
  • 7.3.1. Brazil
  • 7.3.2. Argentina
  • 7.3.3. Others
• 7.4. Europe
  • 7.4.1. Germany
  • 7.4.2. France
  • 7.4.3. United Kingdom
  • 7.4.4. Spain
  • 7.4.5. Others
• 7.5. Middle East and Africa
  • 7.5.1. Saudi Arabia
  • 7.5.2. UAE
  • 7.5.3. Others
• 7.6. Asia Pacific
  • 7.6.1. China
  • 7.6.2. India
  • 7.6.3. Japan
  • 7.6.4. South Korea
  • 7.6.5. Indonesia
  • 7.6.6. Thailand
  • 7.6.7. Others

8. COMPETITIVE ENVIRONMENT AND ANALYSIS

• 8.1. Major Players and Strategy Analysis
• 8.2. Market Share Analysis
• 8.3. Mergers, Acquisitions, Agreements, and Collaborations
• 8.4. Competitive Dashboard

9. COMPANY PROFILES

• 9.1. Pfizer
• 9.2. GSK
• 9.3. Merck
• 9.4. AstraZeneca
• 9.5. Serum Institute of India Pvt Ltd
• 9.6. Sanofi
• 9.7. CSL Limited
• 9.8. Walvax Biotechnology Co. Ltd

10. APPENDIX

• 10.1. Currency
• 10.2. Assumptions
• 10.3. Base and Forecast Years Timeline
• 10.4. Key Benefits for the Stakeholders
• 10.5. Research Methodology
• 10.6. Abbreviations